An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00082617" target="_blank" >RIV/00023001:_____/22:00082617 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10434186
Result on the web
<a href="https://www.tandfonline.com/doi/abs/10.1080/14740338.2021.1978974?journalCode=ieds20" target="_blank" >https://www.tandfonline.com/doi/abs/10.1080/14740338.2021.1978974?journalCode=ieds20</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14740338.2021.1978974" target="_blank" >10.1080/14740338.2021.1978974</a>
Alternative languages
Result language
angličtina
Original language name
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Original language description
Introduction Recent development of novel antidiabetic drugs with proven cardiovascular (CV) and renal benefit and positive effect on body weight enable to take a more complex approach toward the management of type 2 diabetes mellitus (T2DM). Fixed-ratio combinations of insulin-GLP-1 receptor agonist (FRC) utilize complementary mechanisms of action of their individual components and address multiple pathologies linked with T2DM at the same time. Areas covered There are currently three FRCs on the market: iGlarLixi (glargine and lixisenatide in 2 different formulations) and IDegLira (degludec and liraglutide). We provide an up-to-date review on the rationale for the use of FRCs and their current position in the management of T2DM. We discuss the available evidence from randomized controlled trials, post hoc analyses, indirect comparative studies and real-world data on their effect on glycemic control, risk of hypoglycemia, body weight, CV safety, and their safety profile. Expert opinion FRCs represent an efficacious option for treatment intensification from basal insulin or even the first insulin-based therapy in T2DM. Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert opinion on drug safety
ISSN
1474-0338
e-ISSN
1744-764X
Volume of the periodical
21
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
13
Pages from-to
349-361
UT code for WoS article
000707132600001
EID of the result in the Scopus database
2-s2.0-85117219525